BRINGING IV-EQUIVALENT
DIURESIS* TO
THEIR
COMFORT
ZONE
For patients with fluid overload, only FUROSCIX is FDA-approved to deliver subcutaneous, IV-equivalent* treatment at home.
*based on similar systemic exposure and diuresis
Clinical Results
FUROSCIX leverages the standard-of-care diuretic furosemide for a new at-home treatment option for patients with fluid overload.
Learn more about furoscix clinical data
Ease-of-use
98.3% of subjects reported the Instructions for Use were not difficult to follow in a Human Factors study.1
Learn more about furoscix use
Service and support
FUROSCIX DirectSM offers services and support to clinicians, patients, and caregivers to get them started with FUROSCIX.
Learn more about furoscix directReferences: 1. Andre AD, Mohr J, Cornelius B, et al. 2020. Successful validation of a wearable, on-body infusor for subcutaneous administration of Furoscix® in heart failure patients, caregivers, and health care practitioners. [Poster]. The HFSA Virtual Annual Scientific Meeting, September 30 – October 6, 2020.